H. B. F. Antaki, Cairo, circa 1960s
Hekmat Bechir Fathallah Antaki was an Egyptian organic chemist. He completed his doctoral degree at Queen Mary College, University of London, in 1950, under the supervision of J.R. Partington. He returned to Egypt and joined the Research Institute for Tropical Medicine, Cairo, where he conducted an independent programme of research in heterocyclic chemistry between 1951 and 1967. He subsequently served as Director of the Research Institute of Medical Entomology, Cairo.
He published eight papers in four leading chemistry journals between 1951 and 1967. Working without university affiliation, he developed multicomponent condensation methods for the synthesis of pharmacologically relevant heterocyclic scaffolds. His 1962 paper was submitted from his home address in Agouza, Cairo — self-funded research by a working scientist.
His published work was characterized by rigorous bibliographic integrity. His 1965 paper cited foundational research dating back to Bongartz (1888), Stobbe and Volland (1902), and Colange, Dreux and Delplace (1957) — tracking sources spanning 76 years without access to electronic databases, digital libraries, or search engines. Working from Cairo, with whatever physical library resources were available, he credited prior work precisely and completely. He did not claim what was not his.
In 1954, the Egyptian Ministry of Health formally constituted the Unit for Study and Eradication of Malaria in Egypt — an institution whose mission was stated in its name. Antaki joined the unit in 1954 following his return from doctoral study at Queen Mary College, London.
As malaria transmission declined through the late 1950s, the institutional mandate expanded to encompass the broader field of vector-borne disease control. In 1961 the unit was developed into the Research Institute of Medical Entomology — described in its own institutional materials as the only institute in the Arab world specialising in insect-borne diseases and a WHO-designated training centre for vector-borne disease control. Antaki retired in 1983 as its President.
Egypt was certified malaria-free by the World Health Organization on 20 October 2024 — seventy years after the institution was founded and forty-one years after Antaki retired from it.
"Traditional multicomponent reactions such as the Hantzsch, Antaki, and Stankevich methods are discussed alongside more recent green synthetic strategies." — Oduselu et al., Frontiers in Chemistry, 2026.
"The compounds of formula I wherein R is 5-nitro-2-furyl, 3-nitrophenyl and 4-nitrophenyl are known, for example from… Antaki, J. Chem. Soc., 4877 (1963)."
"Suitable reaction conditions are also reported by Antaki in J. Chem. Soc., 4877 (1963)." — US 5,258,390, Imperial Chemical Industries PLC, 1993.
| # | Patent | Assignee | Published | Paper cited |
|---|---|---|---|---|
| 1 | US 3,538,086 | CIBA (Switzerland) | 1970-11-03 | 1951 JCS |
| 2 | US 4,014,881 | Pfizer | 1977-03-29 | 1951 JCS + 1958 JACS |
| 3 | US 4,017,625 | Pfizer | 1977-04-12 | 1951 JCS + 1958 JACS |
| 4 | US 4,022,897 | E.R. Squibb | 1977-05-10 | 1951 JCS |
| 5 | US 4,031,217 | Pfizer | 1977-06-21 | 1951 JCS + 1958 JACS |
| 6 | US 4,041,163 | Pfizer | 1977-08-09 | 1951 JCS |
| 7 | US 4,066,766 | Pfizer | 1978-01-03 | 1951 JCS + 1958 JACS |
| 8 | US 4,122,274 | Bristol-Myers | 1978-10-24 | 1958 JACS |
| 9 | US 4,209,620 | Bristol-Myers | 1980-06-24 | 1958 JACS |
| 10 | US 4,223,031 | Mead Johnson | 1980-09-16 | 1951 JCS |
| 11 | US 4,491,587 | Mead Johnson | 1985-01-01 | 1951 JCS |
| 12 | US 5,166,206 | Merck | 1992-11-24 | 1951 JCS |
| 13 | EP 0539153 | Zeneca | 1993 | 1963 JCS |
| 14 | EP 0539154 | Zeneca | 1993 | 1963 JCS |
| 15 | US 5,258,390 | ICI/AstraZeneca | 1993-11-02 | 1963 JCS |
| 16 | CA 2080950 | ICI / Zeneca | 1993 | 1963 JCS |
| 17 | CA 2080949 | ICI / Zeneca | 1993 | 1963 JCS |
| 18 | US 5,324,729 | Merck | 1994-06-28 | 1951 JCS |
| 19 | US 5,340,819 | ICI | 1994-08-23 | 1951 JCS |
| 20 | US 5,455,253 | Zeneca | 1995-10-03 | 1963 JCS |
| 21 | US 5,484,792 | ICI | 1996 | 1963 JCS |
| 22 | US 5,622,964 | Zeneca | 1997-04-22 | 1963 JCS |
| 23 | US 8,716,319 | Gilead Sciences | 2014-05-06 | 1963 JCS |
| 24 | WO 2015/002150 | Shin Nippon Biomedical Labs | 2015-01-08 | 1951 JCS |
| 25 | US9745274 | Shin Nippon Biomedical Labs | 2017-08-29 | 1951 JCS |
Twenty-five patents verified at text level. Ten independent companies. Six countries. 1970–2016. Full record with remarks: In Their Own Words
In 1911, Palazzo and Tamburini prepared the first compound in the pyrido[1,2-a]pyrimidine series but assigned it the wrong structure (2-oxo instead of 4-oxo). This error was repeated by Seide (1925) and Crippa & Scevola (1937) and remained in the chemical literature for nearly forty years.
In 1951, Hekmat Bechir Fathallah Antaki, working with V. Petrow at Queen Mary College London, resolved the long-standing error. Using an independent synthesis (reacting 2-bromopyridine with ethyl β-aminocrotonate), they conclusively demonstrated that the correct structure was the 4-oxo isomer — borrowing the words of Hermecz and Mészáros (Advances in Heterocyclic Chemistry, Vol. 33, 1983): "unequivocal synthesis." This assignment was later confirmed by Adams and Pachter (1952) and explicitly credited as the definitive proof by Shur and Israelstam (1968) and by Hermecz and Mészáros, who further noted it was "first described by Antaki" (p. 269).
In 1958, in his paper to the Journal of the American Chemical Society — submitted from the Research Institute for Tropical Medicine, Cairo, and received October 15, 1957 — Hekmat Bechir Fathallah Antaki published the first systematic ultraviolet absorption spectra of the pyrido[1,2-a]pyrimidine class (J. Am. Chem. Soc. 1958, 80, 3066–3068). He identified a constant feature across all compounds in the class — intense absorption in the region 330–390 mμ — and provided the mechanistic explanation: conjugative interaction with the β-amino-α,β-unsaturated ketone or nitrile chromophore. He further argued, in his own words:
"This may be considered as evidence for the major contribution of zwitterionic fully aromatic structures such as VIII to the resonance state of the molecule."
This is not a recording of spectral data. It is a structural argument — establishing from spectroscopic evidence the electronic character of an entire compound class. The absorption pattern was not random. It was systematic, mechanistically explained, and structurally significant.
His 1962 paper (J. Org. Chem. 1962, 27, 1371–1374) further clarified the mechanistic origin of these bands. Both assignments were independently confirmed by Shur and Israelstam (1968) and were later adopted as the standard reference by Hermecz and Mészáros in their 1983 canonical review.
Together, the 1951 structural correction and the 1958–1962 UV characterization provided the reliable foundation for the pyrido[1,2-a]pyrimidine series. This foundation enabled much of the subsequent chemical development and the pharmaceutical applications that followed in the decades after.
The heterocyclic scaffolds studied by Dr. Antaki later became relevant in several areas of medicinal chemistry.
The multicomponent dihydropyridine and hexahydroquinoline syntheses — including the Antaki synthesis — belong to the same synthetic lineage that produced widely used calcium-channel-blocking drugs. Bossert and Vater, the inventors of nifedipine, cited Antaki's 1963 paper directly in their 1989 review (Medicinal Research Reviews, 9, 291–324) — twice: as reference 7 in the general synthetic lineage, and as reference 13 in the direct nifedipine chain alongside Knoevenagel (1898). Related drugs in clinical use today include amlodipine (Norvasc), felodipine (Plendil), and nicardipine — prescribed worldwide for hypertension and angina.
Antaki designed his research programme for diseases prevalent in resource-limited settings. His 1962 paper explicitly mentioned work on schistosomicidal activity. The hexahydroquinoline scaffold has since attracted renewed interest in antimalarial drug discovery as resistance to artemisinin-based therapies continues to grow.
The pentacyclic benz[h]indenoquinoline framework first synthesised by Antaki in 1967 belongs to a compound class now studied for DNA intercalation, topoisomerase inhibition, and blue-green fluorescence — properties relevant to both anticancer drug design and bioimaging probes.
| Year | Event |
|---|---|
| 1882 | Hantzsch reports the first dihydropyridine synthesis — the Hantzsch reaction. The Antaki synthesis (1963) produces the fully reduced hexahydroquinoline scaffold, a distinct and more complex ring system. |
| 1888 | Bongartz reports early heterocyclic condensation chemistry — cited by Antaki in 1965 |
| 1902 | Stobbe and Volland contribute to the condensation lineage |
| 1911 | Palazzo and Tamburini obtain the first pyrido[1,2-a]pyrimidine — but assign it the wrong structure |
| 1925 | Seide perpetuates the incorrect formulation |
| 1937 | Crippa and Scevola confirm the wrong structure |
| 1950 | Antaki completes his doctorate at Queen Mary College, London |
| 1951 | Antaki & Petrow resolve the forty-year structural error — definitive proof of the 4-oxo isomer by independent synthesis. Antaki, H.; Petrow, V. J. Chem. Soc. 1951, 551–556. DOI |
| 1954 | Antaki joins the Unit for Study and Eradication of Malaria in Egypt, Cairo. |
| 1958 | First systematic UV spectra for the pyrido[1,2-a]pyrimidine series established, with mechanistic interpretation of the electronic structure of the compound class. Antaki, H. J. Am. Chem. Soc. 1958, 80, 3066–3068. DOI |
| 1962 | First correct mechanistic interpretation of both UV chromophores. Antaki, H. J. Org. Chem. 1962, 27, 1371–1374. DOI |
| 1963 | The Antaki synthesis — first practical three-component hexahydroquinoline synthesis. Antaki, H. J. Chem. Soc. 1963, 4877–4879. DOI |
| 1965 | Decahydroacridine synthesis — extending the scaffold programme to a third ring system |
| 1967 | First synthesis of an intensely blue-fluorescent pentacyclic benz[h]indenoquinoline — paper received by JCS 18 July 1966. Antaki, H. J. Chem. Soc. C 1967, 1581–1582. DOI. In the same year, E. I. Stankevich cites Antaki 1963 as reference 3 in his own paper on hexahydroquinoline synthesis — out of only 9 references, 5 of which are his own. |
| 1972 | Kato et al., Tohoku University, Japan (Chem. Pharm. Bull.) employ "the procedure given by Antaki and Petrow" to prepare authentic reference compounds — using the word "discovered" to describe the 1951 structural assignment. |
| 1973 | Acheson's canonical Chemistry of Heterocyclic Compounds (Wiley, Vol. 9) cites the 1963 and 1965 papers as references 324 and 325 — the standard references for decahydroacridindione synthesis. |
| 1977 | Pfizer and Bristol-Myers independently cite Antaki 1958 in pharmaceutical patents filed within weeks of each other |
| 1983 | Antaki retires as President of the Research Institute of Medical Entomology, Cairo. Hermecz and Mészáros Advances in Heterocyclic Chemistry (Vol. 33) credit the 1951 synthesis as "unequivocal" and note it was "first described by Antaki." |
| 1989 | Bossert and Vater (nifedipine inventors) cite Antaki 1963 twice in Medicinal Research Reviews — as reference 7 and reference 13, the latter placing him in the direct synthetic lineage of nifedipine alongside Knoevenagel (1898). DOI: 10.1002/med.2610090304 |
| 1993 | Houben-Weyl Methoden der Organischen Chemie (E 8a), the German canonical synthetic encyclopedia, cites Antaki and Petrow 1951 as reference 1107. |
| 2011–2024 | Eleven independent research groups reproduce the 8-oxo precursor — none complete the Wolff–Kishner step |
| 2017 | US9745274 granted to Shin Nippon Biomedical Laboratories, Japan, citing the 1951 paper. Patent in force until 2034. |
| 2024 | Egypt certified malaria-free by WHO — 20 October 2024. |
| 2026 | Oduselu et al. (Frontiers in Chemistry) formally names the Antaki synthesis as a classical multicomponent reaction alongside the Hantzsch and Stankevich methods. Citation span confirmed: 75 years, 1951–2026. |